the aid library

LIST OPTIONS

Filter

664

Hepatitis B and liver cancer fact sheet. English.

Cancer Council Victoria (2013) C2

A fact sheet about hepatitis B and its link with liver cancer. It is available in the following languages: English, Arabic, Simplified Chinese, Traditional Chinese, Vietnamese on the website: http:/... more

External Link

Hepatitis B and liver cancer fact sheet. Arabic.

Cancer Council Victoria (2013) C2

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study

Rumgay, H.; Shield, K.; Charvat, H. et al. The Lancet Oncology (2021) CC

The study analyzes the global burden of cancer in 2020 attributable to alcohol consumption. Using data from the GLOBOCAN 2020 database and alcohol consumption patterns, it estimates that 4.1% of all new ca... cases globally (approximately 741,300 cases) were caused by alcohol. The most affected cancers include esophageal, liver, and breast cancer, with heavy drinking contributing the most cases, followed by risky and moderate drinking. The study highlights regional differences, with the highest attributable fractions in Eastern Asia and Central and Eastern Europe. It underscores the need for policies to raise awareness about alcohol-related cancer risks and reduce alcohol consumption globally. more

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (March 2024)

World Health Organization WHO (2024) C_WHO

Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease. The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment cri... more

Depressants - Alcohol

UCLA Brain Research Institute (2021) CC

The pamphlet "Alcohol and Depressants" explains the effects of depressants, including alcohol. Depressants slow brain activity by increasing the release of inhibitory neurotransmitters like GABA, leading to effects such as sedation, decreased anxiety, and reduced heart rate. Alcohol, a legal depress... more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (39)

View PDF (41)

Cancer: Disease Control Priorities, Third Edition (Volume 3)

Gelband H., Jha P., Sankaranarayanan R. et al. International Bank for Reconstruction and Development The World Bank (2015) C2

Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control ...s. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packages that are cost-effective and suited to low-resource settings. Main messages from the volume include: -Quality matters in all aspects of cancer treatment and palliation. -Cancer registries that track incidence, mortality, and survival paired with systems to capture causes of death are important to understanding the national cancer burden and the effect of interventions over time. -Effective interventions exist at a range of prices. Adopting ‘resource appropriate’ measures which allow the most effective treatment for the greatest number of people will be advantageous to countries. -Prioritizing resources toward early stage and curable cancers is likely to have the greatest health impact in low income settings. -Research prioritization is no longer just a global responsibility. more

Download (268)

View PDF (137)

Fact sheet on Cervical Cancer

Cancer Association of South Africa (CANSA) (2021) CC

Download (937)

View PDF (1268)

National Strategy for Cancer Control in Ghana 2012-2016

Ministry of Health, Ghana (2011) C1

Download (207)

View PDF (185)

Kenya National Cancer Treatment Protocols

Ministry of Health, Kenya Ministry of health (2019) C1

The key areas covered are diagnosis, imaging, pathology, surgery, rehabilitation, palliative care and survivorship. It emphasizes a multi-disciplinary team approach which is paramount for quality cancer care. The specific ...s covered are breast, central nervous system, gastrointestinal, gynecological, head and neck, hematological, Kaposi’s sarcoma, lung, prostate and pediatric cancers. They also complement the National Guidelines for Cancer Management in Kenya released in 2013. more

Download (303)

View PDF (371)

Prevention: breast cancer risks factors and prevention

World Health Organization WH=; Pan American Health Organization PAHO (2021) C_WHO

This summary covers the preventive approach to breast cancer control and includes prophylactic medications, prophylactic surgery and lifestyle modifications for breast cancer prevention. Health prof... more

External Link

Cancer in sub-Saharan Africa
recommended

Ngwa, W.; et al. Lancet Oncology Commission (2022) C2

Lancet Oncol 2022; 23: e251–312Published OnlineMay 9, 2022 https://doi.org/10.1016/S1470-2045(21)00720-8 In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions... more

External Link

Comprehensive cervical cancer control: A guide to essential practice
recommended

August Burns, Linda O’Neal Eckert, Susan Hariri et al (2014) C_WHO

This publication gives a broad vision of what a comprehensive approach to cervical cancer prevention and control means. In particular, it outlines the complementary strategies for comprehensive cervical ca... prevention and control, and highlights the neners. This new guide updates the 2006 edition and includes the recent promising deve ed for collaboration across programmes, organizations and partl- opments in technologies and strategies that can address the gaps between the needs for and availability of services for cervical cancer prevention and control. more

Download (763)

View PDF (2039)

Cancer of the Colon and Rectum. Arabic.

Health Information Translations (2012) C1

Download (642)

View PDF (1094)

Cervical Cancer Prevention and Control Policy (South Africa)

Dept. of Health, Republic of South Africa (2021) C1

Cervical cancer, along with maternal deaths, has been identified as a national priority in South Africa as well as other Sub-Saharan African countries. Cervical cancer is the second most common ... among women in South Africa, after breast cancer. Due to limited access to prevention, early diagnosis and treatment, cervical cancer is often fatal. more

Download (710)

View PDF (653)

Breast Cancer Control Policy, South Africa

Dept. of Health, Republic of South Africa (2017) C1

Download (338)

View PDF (532)

Consensus document for management of breast cancer

Indian Council of Medical Research (ICMR) (2016) C1

Prepared as an outcome of ICMR Subcommittee on Breast Cancer |.This consensus document on management of breast cancers summarizes the modalities of treatment including the site-specific anti-... therapies, supportive and palliative care and molecular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies. more

Download (296)

View PDF (288)

Consensus Document for Management of Colorectal Cancer

Indian Council of Medical Research (2014) C1

Prepared as an outcome of ICMR Subcommittee on Colorectal Cancer | Coordinated by Division of Non Communicable Diseases | This Consensus Document on Management of Colorectal Cancer summarizes the mo... more

Download (201)

View PDF (280)

CONSENSUS DOCUMENT FOR MANAGEMENT OF ESOPHAGEAL CANCER

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Esophageal Cancer | This consensus document on management of esophageal cancers summarizes the modalities of treatment including the site-specific an... more

Childhood cancer ‘Signs and Symptoms’ campaign
recommended

Union for International Cancer Control (UICC) (2020) C1

Compilation of campaign materials Accessed on 29 September 2020

Cancer in sub-Saharan Africa recommended

Comprehensive cervical cancer control: A guide to essential practice recommended

Childhood cancer ‘Signs and Symptoms’ campaign recommended

Cancer in sub-Saharan Africa
recommended

Comprehensive cervical cancer control: A guide to essential practice
recommended

Childhood cancer ‘Signs and Symptoms’ campaign
recommended